作者：陈键1，何裕隆1,2

单位：1.中山大学附属第一医院 胃肠外科，广东 广州 510080； 2.中山大学附属第七医院 消化医学中心，广东 深圳 518000

Authors:  CHEN Jian1, HE Yulong1,2

Unit:  1. Gastrointestinal Surgery, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, Guangdong, China;  2. The Center of Digestive Disease, the Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen 518000, Guangdong, China

摘要：

食管胃结合部腺癌是发生于食管和胃交界处的消化系统恶性肿瘤,近年愈受重视并有将其归为一种特殊类型肿瘤的趋势。现有的治疗手段远期疗效仍不尽如人意,靶向治疗为患者生存期延长提供了新的可能。而当下已经投入临床应用的主要是抗HER2靶向药物与抗血管生成药物。本文将针对食管胃结合部腺癌的靶向治疗进展作一综述。

关键词：  食管胃结合部腺癌; HER2; EGFR; 血管生成; 靶向治疗

Abstract：

Adenocarcinoma of the esophagogastric junction (AEG) is a kind of digestive malignant tumor, which locates in esophagogastric junction, is increasingly important and tends to be a specific type of cancer. Long-term results of existing treatments are still poor, while targeted therapies offer new possibilities to improve this situation. Currently, approved targeted therapies are mainly anti-HER2 and anti-angiogenic agents. Herein, we give an overview of advances in targeted therapies for adenocarcinoma of the esophagogastric junction.

Key Words:  Adenocarcinoma of the esophagogastric junction; HER2; EGFR; Angiogenesis; Targeted therapy